Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study

Abstract Background OnabotulinumtoxinA is approved for the prevention of headache in those with chronic migraine (CM); however, more clinical data on the risk-benefit profile for treatment beyond one year is desirable. Methods The Chronic Migraine OnabotulinuMtoxinA Prolonged Efficacy open Label (CO...

Full description

Bibliographic Details
Main Authors: Andrew M. Blumenfeld, Richard J. Stark, Marshall C. Freeman, Amelia Orejudos, Aubrey Manack Adams
Format: Article
Language:English
Published: BMC 2018-02-01
Series:The Journal of Headache and Pain
Subjects:
Online Access:http://link.springer.com/article/10.1186/s10194-018-0840-8